在肯尼亚和乌干达既往接种Ad26.ZEBOV、MVA-BN-Filo埃博拉疫苗方案的HIV阳性成人中接种Ad26.ZEBOV加强疫苗的安全性和免疫原性:一项单臂、开放标签II期临床试验
该研究在肯尼亚和乌干达开展单臂开放标签II期试验,纳入既往接种Ad26.ZEBOV、MVA-BN-Filo初级方案的HIV阳性成人,接种Ad26.ZEBOV加强针并随访28天。加强针耐受良好,未报告重大安全性问题或严重不良事件;加强后7天和21天抗体GMC分别较加强前升高54倍和176倍,两个时间点应答率均为100%。
要点
- HIV阳性成人接种Ad26.ZEBOV加强针耐受良好,多为轻至中度症状,未报告严重不良事件。
- 初级方案后4.5年,24/26(92%)参与者仍被归类为应答者,加强前GMC为726 EU/mL。
- 加强后7天GMC升高54倍至38,965 EU/mL,21天升高176倍至127,959 EU/mL,应答率均100%。
核心结论
- Ad26.ZEBOV加强针在感染控制良好的HIV阳性成人中安全且高度免疫原性。
- Ad26.ZEBOV、MVA-BN-Filo方案可产生至少持续4.5年的长期免疫记忆,并引发强劲的回忆应答。
研究设计与样本
- 在肯尼亚和乌干达开展的单臂、开放标签II期临床试验。
- 纳入感染控制良好且正在接受高效抗逆转录病毒治疗的HIV阳性成人,接种Ad26.ZEBOV加强针并随访28天。
- 主要目标为评估Ad26.ZEBOV加强针安全性和使用Filovirus Animal Non-Clinical Group ELISA检测的抗埃博拉病毒糖蛋白抗体应答。
主要发现
- 加强针耐受良好,症状多为轻至中度,未报告重大安全性问题或严重不良事件。
- 初级方案后4.5年,24/26(92%)参与者仍被归类为应答者,加强前抗体GMC为726 EU/mL(95%CI 447-1179)。
- 加强后7天,GMC升高54倍至38,965 EU/mL(95%CI 23532-64522)。
- 加强后21天,GMC升高176倍至127,959 EU/mL(95%CI 93872-174422)。
- 加强后两个时间点的应答率均为100%。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: People living with HIV constitute an important part of the population in regions at risk of Ebola virus disease outbreaks. The two-dose Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen induces strong immune responses in HIV-positive (HIV+) adults but the durability of this response is unknown. It is also unclear whether this regimen can establish immune memory to enable an anamnestic response upon re-exposure to antigen. METHODS: This paper describes an open-label, phase 2 trial, conducted in Kenya and Uganda, of Ad26.ZEBOV booster vaccination in HIV+ participants who had previously received the Ad26.ZEBOV, MVA-BN-Filo primary regimen. HIV+ adults with well-controlled infection and on highly active antiretroviral therapy were enrolled, vaccinated with booster, and followed for 28 days. The primary objectives were to assess Ad26.ZEBOV booster safety and antibody responses against the Ebola virus glycoprotein using the Filovirus Animal Non-Clinical Group ELISA. RESULTS: The Ad26.ZEBOV booster was well-tolerated in HIV+ adults with mostly mild to moderate symptoms. No major safety concerns or serious adverse events were reported. Four and a half years after the primary regimen, 24/26 (92 %) participants were still classified as responders, with a pre-booster antibody geometric mean concentration (GMC) of 726 ELISA units (EU)/mL (95 %CI 447-1179). Seven days after the booster, the GMC increased 54-fold to 38,965 EU/mL (95 %CI 23532-64522). Twenty-one days after the booster, the GMC increased 176-fold to 127,959 EU/mL (95 %CI 93872-174422). The responder rate at both post-booster time points was 100 %. CONCLUSIONS: The Ad26.ZEBOV booster is safe and highly immunogenic in HIV+ adults with well-controlled infection. The Ad26.ZEBOV, MVA-BN-Filo regimen can generate long-term immune memory persisting for at least 4·5 years, resulting in a robust anamnestic response. TRIAL REGISTRATION: Pan African Clinical Trial Registry (PACTR202102747294430). CLINICALTRIALS: gov (NCT05064956).
引用
- Man-Lik Choi E, Abu-Baker Mustapher G, Omosa-Manyonyi G, et al. Safety and immunogenicity of an Ad26.ZEBOV booster vaccine in Human Immunodeficiency Virus positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against Ebola: A single-arm, open-label Phase II clinical trial in Kenya and Uganda. Vaccine. 2023. PMID: 37981473. doi:10.1016/j.vaccine.2023.10.055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。